Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Waldenström macroglobulinaemia, drawn from the whole corpus: 7 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Indefinite BTKi therapy: cost, toxicity and resistance (BTK C481S).
CXCR4-mutant disease responds slower and shallower.
No approved therapy specific to IgM-related neuropathy.
Transformation to DLBCL (5-10%) is the hardest event to treat.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
WHIM syndrome (warts, hypogammaglobulinaemia, infections and myelokathexis) in patients aged 12 and over
Fewer atrial fibrillation events than ibrutinib.
Zanubrutinib did not significantly increase the complete or very good partial response rate over ibrutinib, but had markedly less cardiovascular and other toxicity; approved for Waldenström macroglobulinaemia in 2021.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.